Trial Search Results

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

The purpose of this study is to see if adding veliparib and/or carboplatin to standard neoadjuvant chemotherapy can help shrink TNBC faster, and lower the risk of the cancer coming back in other parts of the body.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting